American Association for Cancer Research

sorry, we can't preview this file

crc-21-0135-s10.xlsx (9.38 kB)

Supplementary Table ST6 from Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer

Download (9.38 kB)
posted on 2023-04-04, 01:45 authored by Ryan M. Murphy, Jason Tasoulas, Alessandro Porrello, Miranda B. Carper, Yi-Hsuan Tsai, Alisha R. Coffey, Sunil Kumar, Peter YF. Zeng, Travis P. Schrank, Bentley R. Midkiff, Stephanie Cohen, Ashley H. Salazar, Michele C. Hayward, D. Neil Hayes, Andrew Olshan, Gaorav P. Gupta, Anthony C. Nichols, Wendell G. Yarbrough, Chad V. Pecot, Antonio L. Amelio

Crude 5- and 10-year survival rates by p16 cytoplasmic/nuclear status.


HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)

HHS | NIH | National Cancer Institute (NCI)

HHS | NIH | National Institute of General Medical Sciences (NIGMS)

CIHR Vanier Canada Graduate Scholarship

PSI Foundation Fellowship

Wolfe Surgical Research Professorship in the Biology of Head and Neck Cancers Fund

University Cancer Research Fund

UNC Lineberger Tier 3 Developmental Award

Lung Cancer Research Foundation (LCRF)

Free To Breathe (FtB)

North Carolina Biotechnology Translation Research Grant



These findings indicate that codetection of SYNGR3 in immune cells and p16 in tumor cells by IHC can more reliably identify the HPV(+) subgroup of patients with low-risk head and neck cancer that may be appropriate for clinical trials involving treatment deescalation.